Foghorn Therapeutics Inc.
FHTX
$3.87
$0.164.31%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 3.27M | 9.25M | 8.15M | 7.56M | 5.95M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.27M | 9.25M | 8.15M | 7.56M | 5.95M |
| Cost of Revenue | 18.26M | 22.05M | 20.00M | 21.79M | 21.63M |
| Gross Profit | -14.99M | -12.80M | -11.85M | -14.24M | -15.67M |
| SG&A Expenses | 6.58M | 6.80M | 6.65M | 6.86M | 7.24M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 24.84M | 28.84M | 26.65M | 28.65M | 28.87M |
| Operating Income | -21.57M | -19.60M | -18.50M | -21.10M | -22.91M |
| Income Before Tax | -19.88M | -21.66M | -15.85M | -17.94M | -18.83M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -19.88M | -21.66M | -15.85M | -17.94M | -18.83M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.88M | -21.66M | -15.85M | -17.94M | -18.83M |
| EBIT | -21.57M | -19.60M | -18.50M | -21.10M | -22.91M |
| EBITDA | -21.34M | -18.79M | -17.65M | -20.25M | -22.09M |
| EPS Basic | -0.29 | -0.34 | -0.25 | -0.28 | -0.30 |
| Normalized Basic EPS | -0.18 | -0.17 | -0.16 | -0.18 | -0.19 |
| EPS Diluted | -0.29 | -0.34 | -0.25 | -0.28 | -0.30 |
| Normalized Diluted EPS | -0.18 | -0.17 | -0.16 | -0.18 | -0.19 |
| Average Basic Shares Outstanding | 69.54M | 63.07M | 63.03M | 62.98M | 62.85M |
| Average Diluted Shares Outstanding | 69.54M | 63.07M | 63.03M | 62.98M | 62.85M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |